Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Medical Supplies Industry Analysis

UpdatedApr 17, 2026
DataAggregated Company Financials
Companies42
  • 7D2.5%
  • 3M-0.4%
  • 1Y-0.5%
  • YTDn/a

In the last week, the Medical Supplies industry is up 2.5%, with Medline up 2.7%. Despite this gain, the industry's performance has been flat over the past year. As for the next few years, earnings are expected to grow by 21% per annum.

Industry Valuation and Performance

Has the U.S. Medical Supplies Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 18 Apr 2026US$139.5bUS$67.7bUS$1.7b21.9x81.5x2.1x
Mon, 16 Mar 2026US$126.9bUS$67.6bUS$1.9b22.5x66.2x1.9x
Wed, 11 Feb 2026US$140.1bUS$63.6bUS$1.4b28.2x97.3x2.2x
Fri, 09 Jan 2026US$111.5bUS$63.5bUS$958.4m27x116.3x1.8x
Sun, 07 Dec 2025US$74.5bUS$36.1b-US$305,693,601.0024.9x-243.7x2.1x
Tue, 04 Nov 2025US$66.8bUS$36.2b-US$1,444,833,630.0022.9x-46.3x1.8x
Thu, 02 Oct 2025US$65.6bUS$36.1b-US$1,397,203,405.0021.1x-47x1.8x
Sat, 30 Aug 2025US$67.4bUS$36.1b-US$1,395,631,837.0023.5x-48.3x1.9x
Mon, 28 Jul 2025US$76.2bUS$36.0b-US$855,634,228.0025.5x-89.1x2.1x
Wed, 25 Jun 2025US$74.2bUS$36.0b-US$853,312,886.2827.2x-86.9x2.1x
Fri, 23 May 2025US$73.9bUS$35.9b-US$852,935,442.0028.4x-86.7x2.1x
Sun, 20 Apr 2025US$73.1bUS$35.9b-US$634,690,085.0023.9x-115.2x2x
Tue, 18 Mar 2025US$79.2bUS$35.8b-US$590,209,424.0026.1x-134.2x2.2x
Thu, 13 Feb 2025US$86.3bUS$35.5bUS$652.0m24.1x132.3x2.4x
Sat, 11 Jan 2025US$88.5bUS$35.5bUS$709.3m30.2x124.8x2.5x
Mon, 09 Dec 2024US$93.0bUS$35.5bUS$1.2b36.7x80x2.6x
Wed, 06 Nov 2024US$96.8bUS$35.3bUS$1.7b35.9x55.6x2.7x
Fri, 04 Oct 2024US$98.9bUS$35.0bUS$1.6b39.6x60.4x2.8x
Sun, 01 Sep 2024US$97.6bUS$35.0bUS$1.6b39.6x59.5x2.8x
Tue, 30 Jul 2024US$92.9bUS$34.8bUS$2.1b41x44.5x2.7x
Thu, 27 Jun 2024US$87.5bUS$34.8bUS$2.1b40.1x41.6x2.5x
Sat, 25 May 2024US$91.5bUS$34.7bUS$2.1b41.4x44.5x2.6x
Mon, 22 Apr 2024US$90.2bUS$34.2bUS$2.1b36.5x44x2.6x
Wed, 20 Mar 2024US$84.3bUS$26.0bUS$715.6m41.9x117.8x3.2x
Fri, 16 Feb 2024US$81.9bUS$25.9bUS$341.7m45.9x239.6x3.2x
Sun, 14 Jan 2024US$83.4bUS$26.2bUS$280.6m41.3x297.1x3.2x
Tue, 12 Dec 2023US$75.5bUS$26.2bUS$242.3m39.6x311.8x2.9x
Thu, 09 Nov 2023US$72.5bUS$26.1bUS$180.2m38x402.1x2.8x
Sat, 07 Oct 2023US$81.2bUS$25.8b-US$701,784,763.0034.3x-115.7x3.1x
Mon, 04 Sep 2023US$95.3bUS$25.8b-US$702,382,385.0034.4x-135.7x3.7x
Wed, 02 Aug 2023US$99.5bUS$25.2b-US$594,356,355.0035.2x-167.4x3.9x
Fri, 30 Jun 2023US$97.0bUS$25.6b-US$571,798,865.0036.2x-169.6x3.8x
Sun, 28 May 2023US$90.0bUS$25.5b-US$485,450,276.0035.8x-185.4x3.5x
Tue, 25 Apr 2023US$100.7bUS$25.4b-US$343,402,605.0047.7x-293.1x4x
Price to Earnings Ratio

-293.1x


Total Market Cap: US$100.7bTotal Earnings: -US$343,402,605.00Total Revenue: US$25.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Medical Supplies Industry Price to Earnings3Y Average 10.8x202420252026
Current Industry PE
  • Investors are optimistic on the American Health Care Supplies industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 81.5x which is higher than its 3-year average PE of 10.5x.
  • The 3-year average PS ratio of 2.6x is higher than the industry's current PS ratio of 2.1x.
Past Earnings Growth
  • Total earnings for the Health Care Supplies industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 39% per year.
  • This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Comparison

How does U.S. Medical Supplies compare with similar industries?

US Market-29.16%
Healthcare-0.80%
Medical Equipment-0.72%
Medical Supplies2.51%
Medical Equipment-1.12%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
MDLN MedlineUS$47.644.5%
+US$1.7b		n/aPE33.4x
ALGN Align TechnologyUS$190.079.8%
+US$1.2b		10.9%PE33.2x
SOLV SolventumUS$70.487.1%
+US$813.3m		6.4%PE7.9x
AVNS Avanos MedicalUS$24.6273.6%
+US$485.5m		98.1%PS1.6x
LNTH Lantheus HoldingsUS$83.824.0%
+US$209.9m		-17.3%PE23.3x

Latest News

LUCY
US$1.06
Lucyd
7D
-1.9%
1Y
-39.1%
AVNS
US$24.62
Avanos Medical
7D
73.6%
1Y
98.1%
SOLV
US$70.48
Solventum
7D
7.1%
1Y
6.4%

SOLV: 2026 Capital Allocation And Margin Execution Will Support Multiple Expansion

The analyst price target for Solventum has been trimmed by about $5, as analysts factor in more conservative profit margin assumptions and slightly higher required returns, despite mixed recent rating changes on the stock. Analyst Commentary Recent Street research on Solventum reflects a mix of optimism and caution, with target changes and rating shifts clustered around the latest earnings update and subsequent model revisions.
ESTA
US$67.08
Establishment Labs Holdings
7D
11.4%
1Y
113.3%

ESTA: Sustained Adj EBITDA Profitability And US Guidance Will Support Repricing

Analysts have revised the price target for Establishment Labs Holdings to $100, reflecting updated views on discount rates, margins, and long term P/E assumptions following recent sector wide model adjustments and company specific Q4 and guidance commentary. Analyst Commentary Recent research coverage on Establishment Labs Holdings has centered on how the company’s Q4 results, guidance, and sector wide model resets feed into valuation frameworks, particularly around updated P/E assumptions and revised discount rates.
COO
US$70.06
Cooper Companies
7D
-1.6%
1Y
-11.9%

COO: Future Returns Will Depend On Ongoing Buybacks And Myopia Management

Analysts have trimmed their price target for Cooper Companies by about $0.73, reflecting slightly updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News Cooper Companies reports completing a share repurchase of 1,126,600 shares, or 0.58% of its outstanding stock, for $92.43m between November 1, 2025 and January 31, 2026 under its existing buyback program.
STAA
US$25.08
STAAR Surgical
7D
-5.1%
1Y
48.5%

STAAR Surgical: Q1 Preliminary Revenues Justify Decision To Reject Alcon Bid

Apr 09
MDLN
US$47.64
Medline
7D
4.5%
1Y
n/a
HAE
US$61.62
Haemonetics
7D
7.5%
1Y
7.8%

HAE: Vivasure Acquisition Will Support Earnings Quality Despite Sector Repricing

Haemonetics' updated fair value estimate has edged down by about $1, reflecting analysts' recent trims to price targets across the medical technology group, even as they point to healthy sector fundamentals and mixed revisions following the Vivasure acquisition. Analyst Commentary Recent research views on Haemonetics highlight a split between analysts who see upside from the Vivasure acquisition and those who are resetting expectations across the medical technology group after recent sector volatility.
MMSI
US$70.93
Merit Medical Systems
7D
3.9%
1Y
-22.0%

MMSI: 2026 Margin Outlook And Guidance Will Drive Upside Potential

Analysts have trimmed the blended fair value estimate for Merit Medical Systems to about $101 from roughly $104, reflecting a lower projected price target that incorporates higher discount rates, slightly softer revenue growth assumptions, and a more moderate future P/E multiple, even as margin expectations improve. Analyst Commentary Recent Street research on Merit Medical Systems presents a mixed picture, with some analysts trimming targets or ratings on guidance uncertainty, while others still see room for valuation support based on execution and margins.
ADVB
US$4.80
Advanced Biomed
7D
-27.3%
1Y
-86.7%
CUPR
US$0.34
Cuprina Holdings (Cayman)
7D
-4.8%
1Y
-93.2%
LNTH
US$83.82
Lantheus Holdings
7D
4.0%
1Y
-17.3%

Lantheus Holdings: Tensions From The PDUFA Extension

Apr 07
ALGN
US$190.07
Align Technology
7D
9.8%
1Y
10.9%

ALGN: Post Conflict Recovery And Elliott Involvement Will Drive Bullish Repricing

The analyst price target for Align Technology holds at $200, as analysts point to an improved risk/reward skew after the recent pullback and highlight the company as well positioned once regional conflict pressures ease. Analyst Commentary Bullish analysts see the recent pullback as improving the setup for Align Technology, with the stock trading below its February levels after a 15% decline linked to Middle East conflict headlines.
AIDX
US$1.78
20/20 Biolabs
7D
-5.3%
1Y
n/a
RVP
US$0.67
Retractable Technologies
7D
-0.01%
1Y
-3.9%
WOK
US$1.21
WORK Medical Technology Group
7D
-6.9%
1Y
-99.9%